ACA CELL Biotech GmbH
Im Breitspiel 6A
D-69126 Heidelberg



ADVANTAGES AND PROGRESS BEYOND THE STATE-OF-THE-ART

Straightforward ex vivo manipulation of cells by simple one-time addition of antibody to ACA


The use of strictly autologous source avoids any immune reaction and circumvent the need for immunosuppression


Source of stem cells is easily accessible circulating blood




They do not form teratoma




ACA pluripotent stem cells differentiate in situ to the local cell population


No need to treat the patient with growth factors in order to get the stem cells mobilized into peripheral blood


Virtually endless source of cells




No ethical problems related to the source of cells




 
OUR TEAM

Dr. Zorica
Becker-Kojić (Ph.D. Chemistry)

CEO, Co-founder and the leading scientists at R&D Centre for Autologous Adult Stem Cell Therapies Heidelberg Germany.


Ergün
Umur

CEO / Co-founder


Dr. Annie
Schott (Ph.D. Biochemistry)

Project leader and protein specialist


Tamara
Appel

Technician


Oksana
Dzekar

Student


John
Greenacre

IT-Manager


Sabine
Heintzmann

Administration and public relations


Sofia
dos Santos

Marketing / Website

Neuronal differentiation